ArticleAlimentary pharmacology & therapeutics2021
The impact of genetic risk on liver fibrosis in non-alcoholic fatty liver disease as assessed by magnetic resonance elastography.
Article in Alimentary pharmacology & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Integrating genetic and socioeconomic data to predict the progression of nonalcoholic fatty liver disease.American journal of biological anthropology · 2024Article
- Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants.JHEP reports : innovation in hepatology · 2024Article
- Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease.Journal of gastroenterology · 2024Article
- Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies.Annals of the New York Academy of Sciences · 2023Review
- Longitudinal association between overweight years, polygenic risk and NAFLD, significant fibrosis and cirrhosis.Alimentary pharmacology & therapeutics · 2023Article
- Genomic analysis of lean individuals with NAFLD identifies monogenic disorders in a prospective cohort study.JHEP reports : innovation in hepatology · 2023Article
- Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD.Alimentary pharmacology & therapeutics · 2023Review
- Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD.Frontiers in endocrinology · 2023Review
- Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease.The Journal of clinical investigation · 2022Article
- Non-invasive diagnosis and staging of non-alcoholic fatty liver disease.Hormones (Athens, Greece) · 2022Review
- Non-alcoholic fatty liver disease and the impact of genetic, epigenetic and environmental factors in the offspring.World journal of gastroenterology · 2022Review
- Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.Nature reviews. Endocrinology · 2022Review
- Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD.Hepatology (Baltimore, Md.) · 2021Review
- Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundVariants in multiple genetic loci modify the risk of non-alcoholic fatty liver disease (NAFLD) and cirrhosis but there are limited data on the quantitative impact of variant copies on liver fibrosis.
aimTo investigate the effect of PNPLA3, TM6SF2, MBOAT7, GCKR and HSD17B13 genotype on liver fibrosis assessed by magnetic resonance elastography (MRE), a reproducible, accurate, continuous biomarker of liver fibrosis.
methodsThis is a cross-sectional analysis derived from a well-characterised cohort at risk for NAFLD who underwent genotyping and MRE assessment. Liver stiffness (LS) was estimated using MRE and advanced fibrosis was defined as liver stiffness ≥3.63 kilopascals (kPa). Univariable and multivariable linear and logistic regression analysis, were used to assess the association between genotype and MRE.
resultsTwo hundred sixty-four patients (63% women) with a mean age 53 (±17) years, and 31% Hispanic ethnicity with genotyping and MRE were included. The odds of advanced fibrosis were 3.1 (95% CI: 1.1-8.9, P = 0.04) for CG and 6.5 (95% CI: 2.2-18.9, P < 0.01) for GG compared to CC PNPLA3 genotype. Each PNPLA3 risk variant copy was associated with 0.40 kPa (95% CI: 0.19-0.61, P < 0.01) increase in LS on MRE in analysis adjusted for age, sex and BMI and there was significant genotype-age interaction (P < 0.01). Conversely, the protective TA allele in HSD17B13 was associated with a -0.41 kPa (95% CI: -0.76 to -0.05, P = 0.03) decrease in liver stiffness on MRE multivariable analysis.
conclusionKnowledge of PNPLA3 and HSD17B13 genotype may assist in the non-invasive risk stratification of NAFLD with closer monitoring recommended for those with high genetic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.